Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?

Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?

The PROSPER, SPARTAN, and ARAMIS trials demonstrated the efficacy of enzalutamide, apalutamide, and darolutamide, respectively, to extend metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. However, questions remain regarding patient selection for these agents, p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Urology 2019-06, Vol.16 (6), p.335-336
1. Verfasser: Higano, Celestia
Format: Artikel
Sprache:eng
Schlagworte:
692/308/2779/109
692/4025/2768/589/466
692/700/565
692/700/565/2194
Androgens
Bananas
Cancer therapies
Drug therapy
FDA approval
Humans
Male
Medical research
Medicine
Medicine & Public Health
Metastasis
Nervous system
News & Views
news-and-views
Patient Selection
Patients
Phenylthiohydantoin - analogs & derivatives
Phenylthiohydantoin - therapeutic use
Prostate cancer
Prostatic Neoplasms - drug therapy
Pyrazoles - therapeutic use
Quality of life
Thiohydantoins - therapeutic use
Urology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The PROSPER, SPARTAN, and ARAMIS trials demonstrated the efficacy of enzalutamide, apalutamide, and darolutamide, respectively, to extend metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. However, questions remain regarding patient selection for these agents, particularly concerning adverse effects, patient PSA doubling time, and cost and formulary considerations.
ISSN:1759-4812
1759-4820
DOI:10.1038/s41585-019-0186-2